XL Sci-Tech, Inc.

Science & Technology

Contact: Y. Ben Peng

Location: Richland, WA, USA

Email: benpeng@xlscitech.com

Tel: 509.531.3558

Website: http://xlscitech.com

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Larta Institute

National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Medical Devices for treatment of soft tissue cancers.

Company Overview: XL Sci-Tech has been a pioneer in the timed-bioabsorbable microspheres that encapsulate radioisotopes. Its proprietary micro-fabrication process has made the company an innovator in breakthrough brachytherapy seeds for treatment of multiple soft tissue cancers ranging from liver cancer using shorter half-life beta emitting radioisotopes to prostate cancer using low energy gamma emitting radioisotopes.

Target Market(s): Brachytherapy Centers and Radiation Oncology Centers.

Key Value Drivers

Technology: FlexSeeds™ are the first timed bioabsorbable brachytherapy seeds for prostate cancer in the world. They completely eliminate non-absorbable (metal) encapsulation shells and metal X-ray markers in the current prostate seeds. These seeds also offer major post-treatment options plus permit new treatment combinations for prostate cancer and other soft tissue cancers such as breast cancer.

Competitive Advantage: XL Sci-Tech's timed bioabsorbable encapsulation is the only encapsulation technology that distributes medical radioisotopes in a solid-state solution preventing any radioisotope leakage. FlexSeeds™ preserve all the desirable attributes of current prostate seeds while overcoming their major deficiencies. XL Sci-Tech has overcome formidable technological barriers and developed a protectable timed-bioabsorbable biomaterial platform. XL Sci-Tech can also benefit from an accelerated 510(K) FDA process that shortens the time to market and enhances adoption rates.

Plan & Strategy: Seeking strategic partners to accelerate human clinical trials.

*Technology funded in part by the NIH SBIRs and being commercialized under the NIH-CAP.

Management

Leadership:
Y. Ben Peng, President and CEO
Xingye Lei, Clinical Strategy Officer
Ronald Kathren, Radiation Safety Officer
Bernard Hansen: Chief Financial Officer

Scientific Advisory Board:
John Sylvester, M.D. (Invited): Radiation Oncologist, Seattle Prostate Institute
Timothy Mate, M.D. (Invited): Radiation Oncologist, Swedish Hospital, Seattle
Lu Liu: Professor of Nuclear Medicine, Southeast University, China
Ronald Kathren: Professor Emeritus of Pharmaceutical Sciences, Washington State University. Diplomat, American Board of Medical Physics.
Charles Hendricks: Professor Emeritus of Electrical Engineering and Nuclear Engineering, University of Illinois-Urbana.

Product Pipeline